Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced vs Standard Hydration for HDMTX Clearance
NCT03964259Phase 1Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Oct 2019
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in lymphoma and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Virginia Commonwealth University. Primary endpoint: Time elapsed from end of HDMTX to a serum methotrexate level <0.1 micromol/L at 63 Days. Started Oct 2019; status: completed.
02
Conditions
lymphomaacute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03964259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964259.